PKI-587 Gedatolisib PI3K Inhibitors Cas 1197160-78-3
| Size | Price | Stock | Quantity |
|---|---|---|---|
| Get Quotation Now Add to Cart Bulk Inquiry | |||
AddThis Sharing Buttons
| Product name:PKI-587 Gedatolisib | Purity:98% min |
| CAS NO:1197160-78-3 | Solubility:DMSO: 2 mg/mL; H2O: < 1 mg/mL |
| Molecular Formula:C32H41N9O4 | Package:Package according to customer requirements |
| Molecular Weight:615.726 | Storage:Store at -20℃ |
Gedatolisib, also known as PKI-587 and PF-05212384, is an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. Upon intravenous administration, PI3K/mTOR kinase inhibitor PKI-587 inhibits both PI3K and mTOR kinases, which may result in apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy; mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K.
Related Products:
Alpelisib; AS-604850; CAY10505; AS-605240; Apitolisib; PIK-93; PIK-75 Hydrochloride; YM201636; ZSTK474; PI-103; PD98059; GNE-493; MTX-211; AKTIV; Duvelisib; TGX-221; LY294002
[1].Venkatesan AM, et al. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibi
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.